The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.
Psychiatry research June 1, 2025 Jeremy Weleff, Alejandra Pulido-Saavedra, Ardavan Mohammad Aghaei et al. 4 citations
A systematic review of clinical studies on psychedelics for opioid use disorder found few completed trials using serotonergic psychedelics; most investigated ibogaine or ketamine. The evidence is limited by weak study designs focused on opioid withdrawal, few double-blind or placebo-controlled trials, and considerable methodological heterogeneity that makes comparisons across compounds difficult. Most studies had a high risk of bias, mainly due to lack of randomization, blinding, and blinded outcome assessment. The review outlines these limitations and steps to improve the quality of future research in this area.